Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 180

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 4
Chunk 180
---
 research and academic institutions in order to capitalize on the capabilities and technology developed by these entities. We also seek to obtain technologies that complement and expand our existing technology base by entering into license agreements with pharmaceutical and biotechnology companies. When entering into in-license agreements, we generally seek to obtain unrestricted sublicense rights consistent with our primarily partner-driven strategy. We are generally obligated under these agreements to diligently pursue product development, make development milestone payments, pay royalties on any product sales and make payments upon the grant of sublicense rights. We generally insist on the right to terminate any in-license for convenience upon prior written notice to the licensor.
 
The scope of payments we are required to make under our in-licensing agreements is comprised of various components that are paid commensurate with the progressive development and commercialization of our drug products.
 

Our in-licensing agreements generally provide for the following types of payments:
 

•                                Revenue sharing payments. These are payments to be made to licensors with respect                              
    to revenue we receive from sub-licensing to third parties for further development and commercialization of our drug products. These payments
                             are generally fixed at a percentage of the total revenues we earn from these sublicenses.                          
------------------------------------------------------------------------------------------------------------------------------------------------

•                            Milestone payments. These payments are generally linked to the successful achievement                          
    of milestones in the development and approval of drugs, such Phases 1, 2 and 3 of clinical trials and approvals of NDAs, and achievement
                                                              of sales milestones.                                                          
--------------------------------------------------------------------------------------------------------------------------------------------

•                              Royalty payments. To the extent we elect to complete the development, licensing and                            
    marketing of a therapeutic candidate, we are generally required to pay our licensors royalties on the sales of the end drug product. These
    royalty payments are generally based on the net revenue from these sales. In certain instances, the rate of the royalty payments decreases
                           upon the expiration of the drug’s underlying patent and its transition into a generic drug.                        
----------------------------------------------------------------------------------------------------------------------------------------------

•                                   Additional payments. In addition to the above payments, certain of our in-license                                
    agreements provide for a one-time or periodic payment that is not linked to milestones. Periodic payments may be paid until the commercialization
         of the product, either by direct sales or sublicenses to third parties. Other agreements provide for the continuation of these payments     
                                            even following the commercialization of the licensed drug product.                                       
-----------------------------------------------------------------------------------------------------------------------------------------------------
 
The following are descriptions of our in-licensing agreements associated with our therapeutic candidates. In addition to the in